Important Safety Information
Prescribing Information
Patient Support
Visit Our Patient Site
Prescribing Information Patient Websites

Visit Patient Site

IMPORTANT SAFETY INFORMATION:

Dosing

Dosage and Administration

Please follow the dosing instructions carefully.

In This Section

The recommended dosage is as follows:

  • 1 mL (8,500 IU, one full measuring scoop) per meal or snack for patients up to 15 kg (33.07 lbs.) in body weight
  • 2 mL (17,000 IU, two full measuring scoops) per meal or snack for patients over 15 kg (33.07 lbs.) in body weight

Each Sucraid dose should be diluted in 2 to 4 ounces of water, milk or infant formula. Sucraid can be measured with the 1 mL-measuring scoop (provided).

Sucraid Bottles

Administration, Storage, and Shelf Life

The following should be noted with regard to the administration, storage, and expiration of Sucraid:

  • Half of each dose should be taken before the meal and the other half during the meal
  • The beverage or infant formula used to dilute Sucraid should not be heated, nor should Sucraid be added to hot beverages, as heat can decrease the potency of the enzyme
  • Sucraid should not be reconstituted or consumed with fruit juices, as the acidity may impair enzyme activity
  • Sucraid should be refrigerated at 36°F to 46°F (2°C to 8°C) and protected from heat and light
  • Bottles of Sucraid should be discarded four weeks after first opening due to the potential for bacterial growth

Healthcare professionals may recommend that patients avoid dietary sources of starch for the first two weeks of Sucraid treatment, then gradually add starch back into the diet while monitoring symptoms, as Sucraid does not address isomaltase deficiency.

Learn How to Order Sucraid from Our Specialty Pharmacy

References
  1. Sucraid [package insert]. Vero Beach, FL: QOL Medical, LLC; 2017.

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Sucraid may cause a serious allergic reaction. Patients should stop taking Sucraid and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid to observe any signs of acute hypersensitivity reaction.
  • Do not use Sucraid (sacrosidase) Oral Solution with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Although Sucraid provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid to diabetic patients, the physician should consider that Sucraid will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID. Do not put Sucraid in warm or hot fluids. Do not reconstitute or consume Sucraid with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid. Half of the reconstituted Sucraid should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.

Indication

Sucraid®(sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).